TY - JOUR
T1 - Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response
AU - Chiodoni, Claudia
AU - Paglia, Paola
AU - Stoppacciaro, Antonella
AU - Rodolfo, Monica
AU - Parenza, Mariella
AU - Colombo, Mario P.
PY - 1999/7/5
Y1 - 1999/7/5
N2 - We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L) genes to favor interaction of these cells with host dendritic cells (DCs) and, therefore, cross-priming. Cotransduced cells showed reduced tumorigenicity, and tumor take was followed by regression in some mice. In vivo tumors were heavily infiltrated with DCs that were isolated, phenotyped, and tested in vitro for stimulation of tumor-specific cytotoxic T lymphocytes (CTLs). BALB/c C-26 carcinoma cells express the endogenous murine leukemia virus (MuLV) env gene as a tumor-associated antigen. This antigen is shared among solid tumors of BALB/c and C57BL/6 mice and contains two epitopes, AH- 1 and KSP, recognized in the context of major histocompatibility complex class I molecules H-2L(d) and H-2L(b), respectively. DCs isolated from C- 26/GM/CD40L tumors grown in (BALB/c x C57BL/6)F1 mice (H-2(dxb)) stimulated interferon γ production by both anti-AH-1 and KSP CTLs, whereas tumor- infiltrating DCs (TIDCs) of BALB/c mice stimulated only anti-AH-1 CTLs. Furthermore, TIDCs primed naive mice for CTL activity as early as 2 d after injection into the footpad, whereas double-transduced tumor cells required at least 5 d for printing; this difference may reflect direct DC priming versus indirect tumor cell priming. Immunohistochemical staining indicated colocalization of DCs and apoptotic bodies in the tumors. These data indicate that DCs infiltrating tumors that produce GM-CSF and CD40L can capture cellular antigens, likely through uptake of apoptotic bodies, and mature in situ to a stage suitable for antigen presentation. Thus, tumor cell-based vaccines engineered to favor the interaction with host DCs can be considered.
AB - We transduced BALB/c-derived C-26 colon carcinoma cells with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L) genes to favor interaction of these cells with host dendritic cells (DCs) and, therefore, cross-priming. Cotransduced cells showed reduced tumorigenicity, and tumor take was followed by regression in some mice. In vivo tumors were heavily infiltrated with DCs that were isolated, phenotyped, and tested in vitro for stimulation of tumor-specific cytotoxic T lymphocytes (CTLs). BALB/c C-26 carcinoma cells express the endogenous murine leukemia virus (MuLV) env gene as a tumor-associated antigen. This antigen is shared among solid tumors of BALB/c and C57BL/6 mice and contains two epitopes, AH- 1 and KSP, recognized in the context of major histocompatibility complex class I molecules H-2L(d) and H-2L(b), respectively. DCs isolated from C- 26/GM/CD40L tumors grown in (BALB/c x C57BL/6)F1 mice (H-2(dxb)) stimulated interferon γ production by both anti-AH-1 and KSP CTLs, whereas tumor- infiltrating DCs (TIDCs) of BALB/c mice stimulated only anti-AH-1 CTLs. Furthermore, TIDCs primed naive mice for CTL activity as early as 2 d after injection into the footpad, whereas double-transduced tumor cells required at least 5 d for printing; this difference may reflect direct DC priming versus indirect tumor cell priming. Immunohistochemical staining indicated colocalization of DCs and apoptotic bodies in the tumors. These data indicate that DCs infiltrating tumors that produce GM-CSF and CD40L can capture cellular antigens, likely through uptake of apoptotic bodies, and mature in situ to a stage suitable for antigen presentation. Thus, tumor cell-based vaccines engineered to favor the interaction with host DCs can be considered.
KW - CD40 ligand
KW - Cross-Priming
KW - Dendritic cell
KW - Granulocyte/macrophage colony-stimulating factor
KW - Tumor antigens
UR - http://www.scopus.com/inward/record.url?scp=0033526861&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033526861&partnerID=8YFLogxK
U2 - 10.1084/jem.190.1.125
DO - 10.1084/jem.190.1.125
M3 - Article
C2 - 10429676
AN - SCOPUS:0033526861
SN - 0022-1007
VL - 190
SP - 125
EP - 133
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 1
ER -